Ceramic cardiac electrodes

Information

  • Patent Grant
  • 6968236
  • Patent Number
    6,968,236
  • Date Filed
    Monday, January 28, 2002
    23 years ago
  • Date Issued
    Tuesday, November 22, 2005
    19 years ago
Abstract
A cardiac electrode termination pair system that is particularly compatible with Magnetic Resonance Imaging (MRI) procedures. The electrodes include tip and ring electrodes made of a body-compatible ceramic on which is applied via electroplating, sputtered or the like an ultra-thin conductive coating of platinum or titanium or other suitable metal which is compatible with conducting electrical impulses into cardiac tissue. The ring electrode may be adapted for connection to a photonic catheter carrying light signals or a non-photonic catheter carrying electrical signals. The ring (or the tip) may house pulse-delivering components and/or sensing components.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to pacemakers. More particularly, the invention concerns cardiac electrodes for use with pacemakers, and especially pacemakers designed to be compatible with MRI diagnostic apparatus.


2. Description of Prior Art


The metallic cardiac electrodes and leads used in conventional cardiac stimulation and monitoring devices have always been a problem. They tend to fatigue, corrode, and break. Their physical properties (corrosion, strength, chemical activity, etc.) limit the materials which can be used to titanium, platinum metals, their alloys, to certain stainless steels, and to special structures to limit fatigue (such as spring coils, metal cladding, multiple strands, etc.) With respect to metallic leads, a leaky interface is often produced between the metal and the insulating sheath that surrounds the leads.


The problem of metallic leads has been addressed by applicant's assignee in an effort to provide a pacemaker that is compatible with MRI diagnostic imaging procedures. See copending Ser. Nos. 09/864,944 and 09,865,049, both filed on May 24, 2001, and copending Ser. Nos. 09/885,867 and 09/885,868, both filed on Jun. 20, 2001. In these copending patent applications, the contents of which are fully incorporated herein by this reference, MRI compatible/safe pacemakers are disclosed for both implantable and wearable use. The disclosed pacemakers feature photonic catheters carrying optical signals in lieu of metallic leads carrying electrical signals in order to avoid the dangers associated with MRI-generated electromagnetic fields.


The devices of the copending applications also use only non-ferromagnetic materials and attempt to minimize the number of metal components of any kind. In accordance with these goals, the copending applications propose electrodes that are made from non-ferromagnetic metals such as titanium, platinum, and platinum-containing alloys. In addition, the copending applications advise that non-metals may also be used to provide the electrodes. It is the purpose and goal of the present invention to address such non-metallic electrodes and to propose specific nonmetallic electrode constructions that could be used to advantage in an MRI compatible/safe pacemaker, as well as in pacemakers and other electrical stimulation devices that are not necessarily designed for MRI compatibility and safety.


SUMMARY OF THE INVENTION

The foregoing problems are solved and an advance in the art is provided by an electrode termination pair of novel construction for the distal end of a pacemaker catheter, and particularly a photonic pacemaker catheter. The electrode termination pair includes tip and ring structures that are made from a body-compatible ceramic material that is thinly coated, by electroplating, sputtering or other deposition technique, etc., with a suitable electrode metal such as platinum, titanium, or alloys thereof. The tip and ring structures may be formed on separate ceramic base structures or they may be integrated on a single ceramic base structure. If separate structures are used, the tip and ring can be separated by a short insulating stub structure having the same external diameter as the tip and ring. The stub structure can be made of silicone rubber, polyethylene, urethane, or some other material having suitable insulating properties and which is compatible with the human body. The ring structure is electrically connected to the positive electrical pulse output of the pacemaker, and the tip structure is electrically connected to the negative pulse output of the pacemaker. If the electrode termination pair is incorporated in a photonic pacemaker, the ring or the tip can be adapted to house an optical termination and an opto-electric transducer for stimulation pulse delivery to implanted cardiac tissue. The ring or the tip may also house an R-wave amplifier and an electro-optical transducer for pulse monitoring of implanted cardiac tissue. Additional functionality, such as a partial oxygen monitor, may also be provided.


Accordingly, it is a principal object of the invention is to provide “tip and ring” electrode system with no magnetic materials and very little metallic content of any kind.


A further object of the invention is to provide an electrode system for delivering stimulation impulses into cardiac tissue without adverse effect from MRI induced electromagnetic fields, and in a way that will not will not appreciably affect the accuracy of an MRI diagnostic record.


A further object of the invention is to provide an enclosure for an opto-electrical transducer that converts light pulses from a photonic catheter into stimulating electrical impulses to drive the heart.





BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying Drawing in which:



FIG. 1 is an exploded perspective view of an electrode termination pair constructed in accordance with a preferred embodiment of the present invention;



FIGS. 2A and 2B are sectional views taken along the axial centerline of alternative electrode termination pairs constructed in accordance with the embodiment of FIG. 1.



FIGS. 3A and 3B are exploded partial sectional views showing alternative electrode termination pairs constructed in accordance with the embodiment of FIG. 1 and mounted to the end of a photonic catheter and housing an opto-electrical transducer therein;



FIGS. 4A and 4B are exploded partial sectional views showing alternative electrode termination pairs constructed in accordance with the embodiment of FIG. 1 and mounted to the end of a metallic lead catheter;



FIG. 5 is a diagrammatic view of an implantable pacemaker comprising an electrode termination pair in accordance with the invention;



FIG. 6 is a diagrammatic view of a wearable pacemaker comprising an electrode termination pair in accordance with the invention;



FIG. 7 is a perspective view of an electrode termination pair constructed in accordance with a preferred embodiment of the present invention; and



FIGS. 8A and 8B are sectional views taken along the axial centerline of alternative electrode termination pairs constructed in accordance with the embodiment of FIG. 7.





DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Turning now to FIG. 1, a preferred embodiment of the invention is shown in the form of a electrode termination pair 2. The electrode termination pair 2 includes a ceramic cup (tip) 4 and a ceramic ring 6. The tip 4 and the ring 6 are both substantially cylindrical in shape, and preferably have the same wall thickness. Note that the tip 4 has a rounded nose portion and a base portion that is planar. The ring 6 has proximal and distal end portions that are both preferably planar.


As shown in FIGS. 2A and 2B, the tip 4 includes a ceramic base structure 5 and an electrically conductive coating 8. The ring 6 includes a ceramic base structure 7 and an electrically conductive coating 10. The difference between FIGS. 2A and 2B is that all exposed surfaces of the ceramic base structures 5 and 7 are coated in FIG. 2A, whereas only the outer surface of the ceramic base structures 5 and 7 are coated in FIG. 2B.


The material used to form the ceramic base structures 5 and 7 is preferably a suitable bio-compatible ceramic material such a ceramic of the type commonly used for joint prostheses. By way of example only, such material is available from Ceramic Components Inc. of Latrobe, Pa. To form the ceramic base structures 5 and 7, a ceramic slurry is formed into the desired shapes and fired to bake the ceramic material.


The electrically conductive coatings 8 and 10 are preferably formed by very thinly coating the ceramic base structures 5 and 7, as by electroplating, sputtering or other deposition technique, etc., with a suitable metal. If MRI compatibility is desired, the metal preferably has low magnetic susceptibility, such as titanium, platinum, or alloys thereof. Preferably, if MRI compatibility is desired, the coatings 8 and 10 are applied as thin as possible to achieve the twin goals of efficient electrical interaction with an implanted heart while minimizing interaction with MRI induced electromagnetic fields. By way of example, the thickness of the coatings 8 and 10 may range from mono-molecular thickness to sub-micron or micron level thickness. An adhesion promoting sublayer (not shown) may be applied to the ceramic base structures 5 and 7 prior to application of the foregoing coatings.


Turning now to FIGS. 3A and 3B, the electrode termination pair 2 of FIG. 1 may be configured in a tip/ring assembly 12 and mounted to the distal end of a photonic catheter 14 of the type disclosed in the copending applications referenced above. In FIG. 3A, the tip and ring structures 4 and 6 are coated on all surfaces with an electrically conductive coating. In FIG. 3B, only the outside surfaces of the tip 4 and ring 6 are coated.


The tip and ring assembly 12 includes the tip 4, the ring 6, and a short intermediate stub 16 that is solid, generally cylindrical in shape, and made from silicone, polyurethane, polyethylene or other suitable bio-compatible electrically insulating material. The outside diameter of the stub 16 preferably equals the outside diameter of the tip 4 and the ring 6 in order to facilitate efficient implantation and removal in a patient. As described in more detail below, the interior of the stub 16 carries a metallic lead element that extends between the tip 4 and the ring 6. The stub 16 includes a pair of end portions 18 that are preferably of reduced diameter so as to fit snugly inside the tip 4 and the ring 6 and thereby enhance connection integrity. The stub 16 can be implemented as a preformed element whose reduced diameter end portions 18 are respectively attached to the inside walls of the tip 4 and the ring 6 by way of bonding using a suitable medical adhesive. More preferably, however, the stub 16 is cast in place between the tip 4 and the ring 6 using a suitable bio-compatible material, such as silicone, polyurethane, polyethylene or the like. The reduced diameter end portions 18 would then be formed as a result of the stub material being forced into the respective interiors of the tip 4 and the ring 6 prior to hardening into a solid mass.


The photonic catheter 14 is a generally cylindrical element whose exterior sheath 20 is made from silicone, polyurethane, polyethylene or other suitable bio-compatible electrically insulating material. The outside diameter of the sheath 20 is preferably the same as that of the ring 6 in order to facilitate efficient implantation and removal in a patient. As described in more detail below, the interior of the sheath 20 carries one or more optical conductors (e.g., fiber optic elements) that extend to the ring 6 from a photonic pacemaker pulsing unit or other medical device (not shown). The sheath 20 includes a distal end portion 22 that is preferably of reduced diameter so as to fit snugly inside the ring 6 and thereby enhance connection integrity. Like the stub 16, the sheath 20 can be implemented as either a preformed element or can be cast in place. If the sheath 20 is a preformed element, its reduced diameter end portion 22 can be secured to the inside wall of the ring 6 by way of bonding using a suitable medical adhesive. If the sheath 20 is cast in place, the reduced diameter end portion 22 would be formed as a result of the sheath material being forced into the interior of the ring 6 prior to hardening into a solid mass


An optical termination unit 24 is disposed within the ring 6 and is associated with an opto-electrical transducer 26 (described in more detail below). A positive electrical output of the opto-electrical transducer 26 connects to a short metallic lead 28 made from copper or other suitable electrically conductive material of low magnetic susceptance. The metallic lead 28 is electrically connected, as by soldering or the like, to the metallic coating 10 of the ring 6. Note that in FIG. 3B, a small hole 30 can be made in the ring 6 to facilitate electrical connection of the lead 28 to the metallic coating 10. Other connection schemes could also be employed. A negative electrical output of the opto-electrical transducer 26 connects to a longer metallic lead 32 that is also made from copper or other suitable electrically conductive material of low magnetic susceptance. The metallic lead 32 extends through the stub 16 (which is preferably molded around the lead 32 as indicated above) and is electrically connected, as by soldering or the like, to the metallic coating 8 of the tip 4. Note that in FIG. 3B a small hole 34 is made in the tip 4 to facilitate electrical connection of the lead 32 to the metallic coating 8. Again, alternative connection schemes could also be used.


The tip/ring assembly 12 must be small enough to be implantable in a human heart. A diameter of about 5 millimeters or less and an overall length of about 4 centimeters or less should suffice. When the tip/ring assembly 12 is so implanted, the tip 4 will typically be embedded in the endocardial tissue of the heart, while the ring 6 will be situated in one of the chambers of the heart, such as the right ventricle, such that the ring 6 is placed in electrical contact with the endocardium via the patient's ventricular (or atrial) blood. During pacemaker operation, an optical pulse emanating from a photonic pacemaker pulsing unit or other medical device (not shown) is sent down at least one fiber optic element 36 of the photonic catheter 14. The fiber optic element 36 passes into the interior of the ring 6 and is terminated at the optical termination unit 24. The fiber optic element 36 delivers the optical pulse to the opto-electrical transducer 26, which is preferably implemented as a photodiode array situated on or within the optical termination unit 24. The opto-electrical transducer 26 produces an electrical pulse that negatively drives the tip 4 with respect to the ring 6 at a potential of about 3–4 volts and a current level of about 3 milliamperes for a total power output of about 10 milliwatts. The metallic coatings 8 and 10 respectively formed on the tip 4 and the ring 6 will provide highly efficient electrical contact with the heart for delivering the pulse while minimizing the use of metallic material that might otherwise result in complications during MRI imaging. Note that a sensing function for monitoring the heart's “R” wave signals could be added by introducing an R-wave amplifier and an electro-optical transducer (not shown) into the interior of the ring 6 and making appropriate electrical connections to the tip 4 and the ring 6.


Turning now to FIGS. 4A and 4B, the electrode termination pair 2 of FIG. 1 is configured in a tip/ring assembly 40 that is mounted to the distal end of a conventional pacemaker catheter 42. In FIG. 4A, the ceramic base structures 5 and 7 of the tip 4 and the ring 6 are coated on all surfaces with respective electrically conductive coatings 8 and 10. In FIG. 4B, only the outside surfaces of the tip and ring base structures 5 and 7 are coated.


The catheter 42 comprises positive and negative metallic electrode leads 44 and 46, preferably made of MP35 alloy or non-magnetic stainless steel. The leads 44 and 46 are surrounded by a cylindrical sheath 48 made from silicone, polyurethane, polyethylene or other suitable bio-compatible material. The outside diameter of the sheath 48 is selected so as to match the outside diameter of the ring 6. A reduced diameter end portion 50 of the sheath 48 snugly engages the inside wall of the ring 6.


A stub 52 is used to interconnect the tip 4 and the ring 6. The stub 52 can be formed in the same manner as the stub 16 of FIGS. 3A and 3B. The outside diameter of the stub 52 is selected so as to match the outside diameter of the tip 4 and the ring 6. Reduced diameter end portions 54 of the stub 52 respectively engage the inside walls of the tip 4 and the ring 6.


The metallic leads 44 and 46 are respectively connected to the ring 6 and the tip 4. The positive lead 44 extends into the interior of the ring 6 and is electrically connected, as by soldering or the like, to the metallic coating 10. Note that in FIG. 4B, a small hole 56 can be made in the ring 6 to facilitate electrical connection of the lead 28 to the metallic coating 10. Other connection schemes could also be employed. The negative lead 46 extends through the ring 6 and the stub 52 (which is preferably molded around the lead 46 as indicated above) and is electrically connected, as by soldering or the like, to the metallic coating 8 of the tip 4. Note that in FIG. 4B a small hole 58 is made in the tip 4 to facilitate electrical connection of the lead 46 to the metallic coating 8. Again, alternative connection schemes could also be used.


Turning now to FIG. 5, an implantable pacemaker 102 is shown that may be constructed in accordance with the present invention. The pacemaker 102 includes a first (main) enclosure 104 that is connected to the proximal end 106 of a catheter 108, which may be photonic or non-photonic. A distal end 110 of the catheter 108 mounts an electrode termination pair 112 constructed in accordance with a suitable one of the embodiments disclosed herein. Thus, the electrode termination pair 112 includes a coated ceramic tip 114 and a coated ceramic ring 116 separated by a short insulative spacer 118.


Turning now to FIG. 6, a wearable pacemaker 122 is shown that may be constructed in accordance with the present invention. The pacemaker 122 includes a first (main) enclosure 124 that is connected to the proximal end 126 of a catheter 128, which may be photonic or non-photonic. A distal end 130 of the catheter 128 mounts an electrode termination pair 132 constructed in accordance with a suitable one of the embodiments disclosed herein. Thus, the electrode termination pair 132 includes a coated ceramic tip 134 and a coated ceramic ring 136 separated by a short insulative spacer 138.


Turning now to FIG. 7, another preferred embodiment of the invention is shown in the form of a modified electrode termination pair 142. The electrode termination pair 142 includes a tip 144 and a ring 146. As shown in FIGS. 8A and 8B, the tip 144 and the ring 146 are formed on a single ceramic base structure 148. An electrically conductive coating 150 formed at the distal end of the base structure 148 provides the tip 144. An electrically conductive coating 152 formed at the proximal end of the base structure 148 provides the ring 146. The difference between FIGS. 8A and 8B is that both the inside and the outside surfaces of the ceramic base structure 148 are coated in FIG. 8A, whereas only the outer surface of the ceramic base structure 148 is coated in FIG. 8B.


While various embodiments of the invention have been shown and described, it should be apparent that many variations and alternative embodiments could be implemented in accordance with the invention. For example, although the ring 6 has been described as housing components such as the optical termination unit 24 and the opto-electrical transducer 26, these components could potentially be housed in the tip 4 if sufficient space is available within the tip interior. Other components, such as an R-wave amplifier and an electro-optical transducer for generating heartbeat monitoring signals could also be housed in the tip 4 if space permits. Another alternative would be to locate the optical termination unit 24 and the opto-electrical transducer 26 in the tip 4, while placing an R-wave amplifier and an electro-optical transducer in the ring 6. Additional functionality, such as a partial oxygen monitor, a core body temperature sensor, etc., may also be provided.


It is understood, therefore, that the invention is not to be in any way limited except in accordance with the spirit of the appended claims and their equivalents.

Claims
  • 1. A cardiac electrode termination pair system, comprising: a tip, said tip including a bio-compatible ceramic base structure coated with a layer of electrically conductive material;a ring, said ring including a bio-compatible ceramic base structure coated with a layer of electrically conductive material; andan insulative material disposed between said tip and said ring;said coating layer on said tip being formed on outside and inside surfaces of said bio-compatible ceramic base structure associated therewith;said coating layer on said ring being formed on outside and inside surfaces of said bio-compatible ceramic base structure associated therewith.
  • 2. The system in accordance with claim 1, wherein said coating layer on said tip and said ring comprises a metal of low magnetic susceptance.
  • 3. The system in accordance with claim 1, wherein said coating layer on said tip and said ring comprises a metal selected from the group consisting of platinum, titanium, and alloys thereof.
  • 4. A cardiac electrode termination pair system, comprising: a tip, said tip including a bio-compatible ceramic base structure coated with a layer of electrically conductive material;a ring, said ring including a bio-compatible ceramic base structure coated with a layer of electrically conductive material; andan insulative material disposed between said tip and said ring;said ceramic base structures of said tip and said ring being separate structures;said insulative material being a stub separating said tip and said ring.
  • 5. The system in accordance with claim 4, wherein said coating layer on said tip and said ring comprises a metal of low magnetic susceptance.
  • 6. The system in accordance with claim 4, wherein said coating layer on said tip and said ring comprises a metal selected from the group consisting of platinum, titanium, and alloys thereof.
  • 7. The system in accordance with claim 4, wherein said ring or said tip houses an optical termination and an opto-electrical transducer.
  • 8. A cardiac electrode termination pair system, comprising: a tip, said tip including a bio-compatible ceramic base structure coated with a layer of electrically conductive material;a ring, said ring including a bio-compatible ceramic base structure coated with a layer of electrically conductive material; andan insulative material disposed between said tip and said ring;said ceramic base structures of said ring and said tip being integrated as a single ceramic base structure;said insulative material being an area of said single ceramic base structure.
  • 9. The system in accordance with claim 8, wherein said coating layer on said tip and said ring comprises a metal of low magnetic susceptance.
  • 10. The system in accordance with claim 8, wherein said coating layer on said tip and said ring comprises a metal selected from the group consisting of platinum, titanium, and alloys thereof.
US Referenced Citations (284)
Number Name Date Kind
3057356 Greatbatch Oct 1962 A
3478746 Greatbatch Nov 1969 A
3508167 Russell, Jr. Apr 1970 A
3669095 Kobayashi et al. Jun 1972 A
3686958 Porter et al. Aug 1972 A
3718142 Mulier Feb 1973 A
3789667 Porter et al. Feb 1974 A
3825015 Berkovits Jul 1974 A
4012641 Brickerd, Jr. et al. Mar 1977 A
4041954 Ohara Aug 1977 A
4050004 Greatbatch Sep 1977 A
4071032 Schulman Jan 1978 A
4091818 Brownlee et al. May 1978 A
4149542 Thoren Apr 1979 A
4200110 Peterson et al. Apr 1980 A
4210029 Porter Jul 1980 A
4254776 Tanie et al. Mar 1981 A
4325382 Miodownik Apr 1982 A
4333053 Harrison et al. Jun 1982 A
4341221 Testerman Jul 1982 A
4379262 Young Apr 1983 A
4432363 Kakegawa Feb 1984 A
4450408 Tiemann May 1984 A
4476870 Peterson et al. Oct 1984 A
4491768 Slicker Jan 1985 A
4506680 Stokes Mar 1985 A
4545381 Bournay, Jr. et al. Oct 1985 A
4611127 Ibrahim et al. Sep 1986 A
4677471 Takamura et al. Jun 1987 A
4682596 Bales et al. Jul 1987 A
4686964 Yunoki et al. Aug 1987 A
4691164 Haragashira Sep 1987 A
4692347 Yasuda Sep 1987 A
4719159 Clark et al. Jan 1988 A
4727874 Bowers et al. Mar 1988 A
4763075 Weigert Aug 1988 A
4784461 Abe et al. Nov 1988 A
4798443 Knipe et al. Jan 1989 A
4800883 Winstrom Jan 1989 A
4804244 Hasegawa et al. Feb 1989 A
4827906 Robicsek et al. May 1989 A
4827934 Ekwall May 1989 A
4844099 Skalsky et al. Jul 1989 A
4858610 Callaghan et al. Aug 1989 A
4879992 Nishigaki et al. Nov 1989 A
4880004 Baker, Jr. et al. Nov 1989 A
4903701 Moore et al. Feb 1990 A
4911525 Hicks et al. Mar 1990 A
4930521 Metzger et al. Jun 1990 A
4934785 Mathis et al. Jun 1990 A
4987897 Funke Jan 1991 A
4991590 Shi Feb 1991 A
5010888 Jadvar et al. Apr 1991 A
5029588 Yock et al. Jul 1991 A
5055810 deLaChapelle et al. Oct 1991 A
5058586 Heinze Oct 1991 A
5061680 Paulson et al. Oct 1991 A
5089697 Prohaska Feb 1992 A
5113859 Funke May 1992 A
5131409 Lobarev et al. Jul 1992 A
5154387 Trailer Oct 1992 A
5158932 Hinshaw et al. Oct 1992 A
5168871 Grevious Dec 1992 A
5178149 Imburgia et al. Jan 1993 A
5214730 Nagasawa et al. May 1993 A
5217009 Kronberg Jun 1993 A
5217010 Tsitlik et al. Jun 1993 A
5226210 Koskenmaki et al. Jul 1993 A
5240004 Walinsky et al. Aug 1993 A
5243979 Stein et al. Sep 1993 A
5265602 Anderson et al. Nov 1993 A
5267564 Barcel et al. Dec 1993 A
5324310 Greeninger et al. Jun 1994 A
5330512 Hauck et al. Jul 1994 A
5348010 Schnall et al. Sep 1994 A
5354220 Ganguly et al. Oct 1994 A
5370668 Shelton Dec 1994 A
5387229 Poore Feb 1995 A
5387232 Trailer Feb 1995 A
5402070 Shelton et al. Mar 1995 A
5410413 Sela Apr 1995 A
5415653 Wardle et al. May 1995 A
5425373 Causey, III Jun 1995 A
5435308 Gallup et al. Jul 1995 A
5435316 Kruse Jul 1995 A
5438987 Thacker et al. Aug 1995 A
5445151 Darrow et al. Aug 1995 A
5453838 Danielian et al. Sep 1995 A
5454837 Lindegren et al. Oct 1995 A
5456698 Byland et al. Oct 1995 A
5464014 Sugahara Nov 1995 A
5476095 Schnall et al. Dec 1995 A
5520190 Benedict et al. May 1996 A
5523534 Meister et al. Jun 1996 A
5569158 Suzuki et al. Oct 1996 A
5570671 Hickey Nov 1996 A
5574811 Bricheno et al. Nov 1996 A
5575772 Lennox Nov 1996 A
5582170 Soller Dec 1996 A
5590227 Osaka et al. Dec 1996 A
5601611 Fayram et al. Feb 1997 A
5603697 Grundy et al. Feb 1997 A
5604433 Theus et al. Feb 1997 A
5611016 Fangmann et al. Mar 1997 A
5619605 Ueda et al. Apr 1997 A
5626618 Ward et al. May 1997 A
5626619 Jacobson et al. May 1997 A
5631988 Swirhun et al. May 1997 A
5634720 Gallup et al. Jun 1997 A
5649965 Pons et al. Jul 1997 A
5653735 Chen et al. Aug 1997 A
5654317 Fujioka et al. Aug 1997 A
5658966 Tsukamoto et al. Aug 1997 A
5679026 Fain et al. Oct 1997 A
5683435 Truex et al. Nov 1997 A
5697958 Paul et al. Dec 1997 A
5699801 Atalar et al. Dec 1997 A
5709225 Budgifvars et al. Jan 1998 A
5716386 Ward et al. Feb 1998 A
5723856 Yao et al. Mar 1998 A
5733247 Fallon Mar 1998 A
5738105 Kroll Apr 1998 A
5749910 Brumwell et al. May 1998 A
5752977 Grevious et al. May 1998 A
5755739 Sun et al. May 1998 A
5755742 Schuelke et al. May 1998 A
5759197 Sawchuk et al. Jun 1998 A
5761354 Kuwano et al. Jun 1998 A
5766227 Nappholz et al. Jun 1998 A
5766527 Schildgen et al. Jun 1998 A
5772604 Langberg et al. Jun 1998 A
5774501 Halpern et al. Jun 1998 A
5776167 Levine et al. Jul 1998 A
5776168 Gunderson Jul 1998 A
5782241 Felblinger et al. Jul 1998 A
5782880 Lahtinen et al. Jul 1998 A
5808730 Danielian et al. Sep 1998 A
5814087 Renirie Sep 1998 A
5814089 Stokes et al. Sep 1998 A
5814090 Latterell et al. Sep 1998 A
5814091 Dahlberg et al. Sep 1998 A
5817130 Cox et al. Oct 1998 A
5817133 Houben Oct 1998 A
5817136 Nappholz et al. Oct 1998 A
5818990 Steijer et al. Oct 1998 A
5827195 Lander Oct 1998 A
5827997 Chung et al. Oct 1998 A
5830209 Savage et al. Nov 1998 A
5836895 Ramsey, III Nov 1998 A
5861012 Stroebel Jan 1999 A
5865839 Doorish Feb 1999 A
5867361 Wolf et al. Feb 1999 A
5868664 Speier et al. Feb 1999 A
5869412 Yenni, Jr. et al. Feb 1999 A
5870272 Seifried et al. Feb 1999 A
5871509 Noren Feb 1999 A
5871512 Hemming et al. Feb 1999 A
5873898 Hemming et al. Feb 1999 A
5882108 Fraizer Mar 1999 A
5882305 Dumoulin et al. Mar 1999 A
5891171 Wickham Apr 1999 A
5895980 Thompson Apr 1999 A
5897577 Cinbis et al. Apr 1999 A
5899927 Ecker et al. May 1999 A
5902326 Lessar et al. May 1999 A
5916162 Snelten et al. Jun 1999 A
5916237 Schu Jun 1999 A
5917625 Ogusu et al. Jun 1999 A
5919135 Lemelson Jul 1999 A
5928145 Ocali et al. Jul 1999 A
5928270 Ramsey, III Jul 1999 A
5928570 Reo Jul 1999 A
5940554 Chang et al. Aug 1999 A
5946086 Bruce Aug 1999 A
5951596 Bellinger Sep 1999 A
5954660 Legay et al. Sep 1999 A
5957857 Hartley Sep 1999 A
5963034 Mahapatra et al. Oct 1999 A
5963690 Cheng Oct 1999 A
5967977 Mullis et al. Oct 1999 A
5968083 Ciciarelli et al. Oct 1999 A
5973779 Ansari et al. Oct 1999 A
5973906 Stevenson et al. Oct 1999 A
5978710 Prutchi et al. Nov 1999 A
5982961 Pan et al. Nov 1999 A
5985129 Gough et al. Nov 1999 A
5987995 Sawatari et al. Nov 1999 A
5999853 Stoop et al. Dec 1999 A
5999857 Weijand et al. Dec 1999 A
6005191 Tzeng et al. Dec 1999 A
6011994 Kronberg Jan 2000 A
6013376 Yenni, Jr. Jan 2000 A
6016448 Busacker et al. Jan 2000 A
6016477 Ehnebuske et al. Jan 2000 A
6023641 Thompson Feb 2000 A
6024738 Daikuzono et al. Feb 2000 A
6026316 Kucharczyk Feb 2000 A
6029086 Kim et al. Feb 2000 A
6029087 Wohlgemuth Feb 2000 A
6031710 Wolf et al. Feb 2000 A
6036639 Allred, III et al. Mar 2000 A
6036654 Quinn et al. Mar 2000 A
6044301 Hartlaub et al. Mar 2000 A
6052613 Takaki Apr 2000 A
6052614 Morris, Sr. et al. Apr 2000 A
6052623 Fenner et al. Apr 2000 A
6055455 O'Phelan et al. Apr 2000 A
6056415 Alled, III et al. May 2000 A
6056721 Shulze May 2000 A
6064906 Langberg et al. May 2000 A
6066096 Smith et al. May 2000 A
6067472 Vonk et al. May 2000 A
6076003 Rogel Jun 2000 A
6080829 Tapsak et al. Jun 2000 A
6090473 Yoshikawa et al. Jul 2000 A
6090728 Yenni, Jr. et al. Jul 2000 A
6091015 del Valle et al. Jul 2000 A
6091744 Sorin et al. Jul 2000 A
6091987 Thompson Jul 2000 A
6101973 Stewart et al. Aug 2000 A
6118910 Chang Sep 2000 A
6119031 Crowley Sep 2000 A
6129745 Sun et al. Oct 2000 A
6134003 Tearney et al. Oct 2000 A
6134478 Spehr Oct 2000 A
6142678 Cheng Nov 2000 A
6144205 Souza et al. Nov 2000 A
6144866 Miesel et al. Nov 2000 A
6144881 Hemming et al. Nov 2000 A
6146415 Fitz Nov 2000 A
6148222 Ramsey, III Nov 2000 A
6148229 Morris, Sr. et al. Nov 2000 A
6149313 Giebel et al. Nov 2000 A
6163724 Hemming et al. Dec 2000 A
6166806 Tjin Dec 2000 A
6169921 Knight et al. Jan 2001 B1
6171240 Young et al. Jan 2001 B1
6173203 Barkley et al. Jan 2001 B1
6179482 Takizawa et al. Jan 2001 B1
6188926 Vock Feb 2001 B1
6192261 Gratton et al. Feb 2001 B1
6198968 Prutchi et al. Mar 2001 B1
6198972 Hartlaub et al. Mar 2001 B1
6208899 Kroll Mar 2001 B1
6216041 Tierney et al. Apr 2001 B1
6223083 Rosar Apr 2001 B1
6226545 Gilderdale May 2001 B1
6230060 Mawhinney May 2001 B1
6236879 Konings May 2001 B1
6238686 Burrell et al. May 2001 B1
6240317 Villaseca et al. May 2001 B1
6245020 Moore et al. Jun 2001 B1
6246910 Bonnet et al. Jun 2001 B1
6247474 Greeninger et al. Jun 2001 B1
6254632 Wu et al. Jul 2001 B1
6256537 Stoop et al. Jul 2001 B1
6256541 Heil et al. Jul 2001 B1
6258087 Edwards et al. Jul 2001 B1
6259843 Kondo Jul 2001 B1
6259954 Conger et al. Jul 2001 B1
6263229 Atalar et al. Jul 2001 B1
6263242 Mika et al. Jul 2001 B1
6266555 Werner et al. Jul 2001 B1
6266563 Knight et al. Jul 2001 B1
6266564 Hill et al. Jul 2001 B1
6266566 Nichols et al. Jul 2001 B1
6270457 Bardy Aug 2001 B1
6270831 Kumar et al. Aug 2001 B2
6272377 Sweeney et al. Aug 2001 B1
6272380 Warman et al. Aug 2001 B1
6274265 Kraska et al. Aug 2001 B1
6275730 Knight et al. Aug 2001 B1
6275732 Hsu et al. Aug 2001 B1
6275734 McClure et al. Aug 2001 B1
6277078 Porat et al. Aug 2001 B1
6277107 Lurie et al. Aug 2001 B1
6278057 Avellanet Aug 2001 B1
6278277 Zeiger Aug 2001 B1
6278894 Salo et al. Aug 2001 B1
6278897 Rutten et al. Aug 2001 B1
6296654 Ward Oct 2001 B1
6317633 Jorgenson et al. Nov 2001 B1
6367984 Stephenson et al. Apr 2002 B1
6571130 Ljungstrom et al. May 2003 B1
Foreign Referenced Citations (1)
Number Date Country
WO 0174241 Oct 2001 WO
Related Publications (1)
Number Date Country
20030144717 A1 Jul 2003 US